Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 1910 first-in-human in advanced solid tumors
2022-503066-74-00Phase 2Completed
- Sponsor
- BioInvent International
- Start
- Dec 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 6
01
Overview
Phase 2, open-label trial of BI-1910 in Nonhematologic neoplasms (2 arms), sponsored by BioInvent International. Primary endpoints: Safety and tolerability (AEs and SAEs), Dose-limiting toxicities (DLTs) and 1 more. Started Dec 2023; status: completed.
02
Drugs
BI-1910
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on 2022-503066-74-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-503066-74-00.